The Frequencies and Clinical Implications of Mutations in 33 Kinase-Related Genes in Locally Advanced Rectal Cancer: A Pilot Study

Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma

(2013) Marjun P. Duldulao et al.   ANNALS OF SURGICAL ONCOLOGY

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

(2013) Howard A. Burris   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance

(2012) Edita Aksamitiene et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers

(2012) Y. Imamura et al.   CLINICAL CANCER RESEARCH

PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

(2012) Arjun Sood et al.   Clinical Colorectal Cancer

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

(2012) Antonella De Luca et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study

(2012) Pei-Long Sun et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

(2012) Nathan T. Ihle et al.   JNCI-Journal of the National Cancer Institute

EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients

(2011) S. Hu-Lieskovan et al.   CLINICAL CANCER RESEARCH

Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes

(2011) Li-E Wang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy

(2011) Janine M Davies et al.   Radiation Oncology

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy

(2010) C Bengala et al.   BRITISH JOURNAL OF CANCER

KRAS and BRAF Mutations and PTEN Expression Do Not Predict Efficacy of Cetuximab-Based Chemoradiotherapy in Locally Advanced Rectal Cancer

(2010) Philipp Erben et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Preoperative Chemoradiation With Cetuximab, Irinotecan, and Capecitabine in Patients With Locally Advanced Resectable Rectal Cancer: A Multicenter Phase II Study

(2010) Sun Young Kim et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer

(2009) Shuji Ogino et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy

(2009) Jochen Gaedcke et al.   RADIOTHERAPY AND ONCOLOGY

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

Prognostic Value of Pathologic Complete Response After Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Long-Term Analysis of 566 ypCR Patients

(2008) Carlo Capirci et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY